Evidence map›Paper›PMID 27931552›Full record

Trial reportIndian heart journal

Effects of sustained-release trimetazidine on chronically dysfunctional myocardium of ischemic dilated cardiomyopathy - Six months follow-up result.

A Momen, M Ali, P K Karmakar, M Z Ali, A Haque, M R Khan, M I Khalil, M S Hossain, R M Huda, M N Goni

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Indian heart journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 5 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 5 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trimetazidine in Cardiovascular Disease and Beyond: A Comprehensive Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Review
  9. Trimetazidine in Heart Failure.Frontiers in pharmacology · 2020
    Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

A MomenNational Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh. Electronic address: abdulmomen71@yahoo.com.
M AliProfessor and Head, Department of Cardiology, National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh.
P K KarmakarAssistant Professor, Cardiology, National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh.
M Z AliAssistant Professor, Cardiology, National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh.
A HaqueAssistant Professor, Cardiology, National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh.
M R KhanAssistant Professor, Cardiology, National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh.
M I KhalilAssistant Professor, Cardiology, National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh.
M S HossainAssistant Professor, Cardiology, National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh.
R M HudaAssistant Professor, Cardiology, National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh.
M N GoniAssistant Professor, Cardiology, National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh.
National Institute of Cardiovascular Diseases · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIschemic cardiomyopathy is a growing burden in third world countries. So far, benefits of trimetazidine in this group of patients have been suggested by clinical trials mainly conducted in Europe. We evaluated the effect of trimetazidine on ischemic dilated cardiomyopathy in our population. METHODS AND

results98 patients (aged 58.5±9.2 years), admitted with decompensated heart failure with previous history of MI and/or documentation of significant CAD with previous CAG, were chosen for the study. Patients were randomized into two groups - one provided with trimetazidine 35mg sustained released tablet, twice daily and the other with a placebo, along with other conventional medications. Patients were included if they had dilated LV (LVIDd>57mm) and left ventricular ejection fraction (LVEF) ≤40%. After 6 months, significantly higher number of patients in trimetazidine group were in NYHA class I (22% vs. 8%, p=0.03) and class II (56% vs. 34%, p=0.01); higher number of patients in placebo group were in NYHA class III class IV. Anginal episodes and use of sublingual nitrate per week were significantly lower in the trimetazidine group. Left ventricular diastolic dimension (59.7±5.2 vs. 65.1±6.1, p=0.001) was significantly different in the two groups as was the increase of LVEF (11% vs. 5.6%, p=0.001). Hospitalization for worsening heart failure was significantly lower in trimetazidine group (13 vs. 22, p=0.047).

conclusionTrimetazidine seems to be beneficial in patients with ischemic dilated cardiomyopathy in South Asian population and larger scale study with extended follow-up is needed.

Indexed as

Cardiomyopathy, DilatedDelayed-Action PreparationsDose-Response Relationship, DrugDouble-Blind MethodEchocardiographyFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial ContractionTime FactorsTreatment OutcomeTrimetazidineVasodilator AgentsVentricular Function, LeftDelayed-Action PreparationsTrimetazidineVasodilator AgentsChronic heart failureIschemic cardiomyopathyTrimetazidine

Identifiers

PMID27931552
PMCPMC5143824
OpenAlexW2337319204

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.